SEATTLE GENETICS
BiotechSEATTLE GENETICS is a biotechnology company focused on Oncology. Key products include ADCETRIS.
SEATTLE GENETICS's Key Drugs
SEATTLE GENETICS's core commercial portfolio centers on ADCETRIS, spanning Oncology — its most strategically important drugs approved in the last 15 years.
SEATTLE GENETICS's Recent FDA Approvals
New NDA/BLA approvals for SEATTLE GENETICS over the last two years — novel drugs only, excluding generics and label supplements.
SEATTLE GENETICS's Therapeutic Areas
SEATTLE GENETICS's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SEATTLE GENETICS's Top Competitors
SEATTLE GENETICS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SEATTLE GENETICS Pipeline Snapshot
Active clinical trials for SEATTLE GENETICS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2011-08-19
- Latest
- 2025-02-11
- Applications
- 2